Invitro Antitumor Activities of a Novel 2/3 Condensation Product of Salicylaldoxime With Di-n-butyltin(iv) Oxide

Boualam, M.;Biesemans, M.;Meunierpiret, J.;Willem, R.;Gielen, M.
(1992) INTERNATIONAL CONF ON ENVIRONMENTAL AND BIOLOGICAL ASPECTS OF MAIN-GROUP ORGANOMETALS ( ICEBAMO ) — Location: PADUA(Italy) (15.September.1991)

Files

No attached file found for this publication.

Details

Authors
  • Boualam, M.
    Author
  • Biesemans, M.
    Author
  • Meunierpiret, J.
    Author
  • Willem, R.
    Author
  • Gielen, M.
    Author
Abstract
The antitumor activities of three novel condensation products of salicylaldoxime with di-n-butyltin(IV) oxide (compound 1), di-t-butyltin oxide (compound 2) and diphenyltin oxide (compound 3) are presented. Against MCF-7, a human mammary tumor cell line, compounds 1 and 2 are characterized by inhibition doses ID50 in vitro of 67 and 49 ng cm-3 respectively, whereas cis-platin, an antitumor drug used clinically, has an ID50 of 850 ng cm-3. Against WiDr, a colon carcinoma, they also score better than cis-platin: 215 and 121 ng cm-3 versus 624 ng cm-3. In contrast, the diphenyltin compound, 3, is inactive against both tumor cell lines. The results of a pre-screening performed on compound 1 by the National Cancer Institute (NCI) on a panel of 60 human tumor cell lines show that two of the selectivity parameters calculated by the NCI for that compound are statistically significant, namely D(GI50) (51.9 > 50) and MGD(H) (80.1 > 75). One is almost satisfactory (D(H) = 72.4 = ca 75). The other two, D(TGI) (40.0 < 50) and D(LC50) (16.7 << 50) are not.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Boualam, M., Biesemans, M., Meunierpiret, J., Willem, R., & Gielen, M. (1992). Invitro Antitumor Activities of a Novel 2/3 Condensation Product of Salicylaldoxime With Di-n-butyltin(iv) Oxide. Applied Organometallic Chemistry, 6(2), 197-205. https://doi.org/10.1002/aoc.590060214 (Original work published 1992)